Pulse Biosciences stock traded up following an earnings report, and its pivotal study enrollment is ahead of schedule.
5 reports, 2 independent
Updated Sep 10
Gone quiet
- Reports
- 5
- Developments
- 4
- Repetition
- 60%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Pulse Biosciences stock traded up following an earnings report, and its pivotal study enrollment is ahead of schedule.
How it developed
Newest first. Tap a step to see who reported it.- Analyst firm Freedom Capital Markets initiated coverage on Pulse Biosciences stock.Sub-event
Analyst ratings and price targets released for Pulse Biosciences.1 source
- Pulse Biosciences presented European feasibility data at the Heart Rhythm Society meeting.Sub-event
Pulse Biosciences stock rises on earnings, while its clinical study enrollment accelerates.1 source